Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan-hyaluronic acid complex

Drug Profile

Irinotecan-hyaluronic acid complex

Alternative Names: HA-irinotecan; Hyaluronan irinotecan complex; Hyaluronic acid irinotecan complex; HyCAMP; Irinotecan hyaluronan complex

Latest Information Update: 01 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Monash University
  • Developer Alchemia
  • Class Alkaloids; Antineoplastics; Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Small cell lung cancer
  • Suspended Colorectal cancer

Most Recent Events

  • 01 May 2015 Irinotecan-hyaluronic acid complex is still in phase II development for Small cell lung cancer in Australia
  • 01 May 2015 Alchemia suspends a phase II trial in Colorectal cancer in Australia (NCT02216487)
  • 29 Jan 2015 Suspended - Phase-III for Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Poland, Ukraine, Serbia, Russia, Bulgaria, United Kingdom, Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top